Bristol Myers Squibb is acquiring an antibody-drug conjugate to treat bone and blood cancers from multinational biotechnology startup Orum Therapeutics, the companies announced Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,